InVivoMAb anti-human/monkey MDR-1 (CD243) BE0340-R100mg from Bio X Cell

Description

Bio X Cell InVivoMAb anti-human/monkey MDR-1 (CD243) Monoclonal Antibody has the following reported applications: in vivo MDR-1 blocking/depletion in xenogeneic murine, tumor models, in vitro MDR-1 blocking, Immunohistochemistry (paraffin). It features greater than 95% purity, ultra-low endotoxin levels, and are preservative, stabilizer, and carrier protein-free

Product Specs
ItemInVivoMAb anti-human/monkey MDR-1 (CD243)
CompanyBio X Cell
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberBE0340-R100mg
Antibody TypePrimary Antibody
TargetMDR-1
CloneUIC2
IsotypeIgG2a, κ
Purity>95%, Determined by SDS-PAGE
HostMouse
ConcentrationLot specific,typically between 4-11 mg/ml
ClonalityMonoclonal
Quantity100 mg
Conjugate/TagUnconjugated
Immunogen3T3 fibroblasts transfected with human CD243 cDNA
Applicationsin vivo MDR-1 blocking/depletion in xenogeneic murine, tumor models, in vitro MDR-1 blocking, Immunohistochemistry (paraffin)
ReactivityHuman, Monkey
NCBI Full Gene NameATP binding cassette subfamily B member 1
NCBI Gene AliasesABC20, CD243, CLCS, GP170, MDR1, P-GP, PGY1, p-170
FormatPBS, pH 7.0, Contains no stabilizers or preservatives
Research AreaCancer Biology, Immunology

Specifications/Features

Other available quantities: Available in 1, 5, 10, 25, 50, 100 mg and bulk sizes. Academic discount available.

Endotoxin: <2EU/mg (<0.002EU/µg), Determined by LAL gel clotting assay

Add to Compare List

Bio X Cell

39 Labombard Rd

Lebanon, NH 03766

United States

Phone: 1-866-787-3444

Email: customerservice@bxcell.com

Company Profile

Website: bioxcell.com

(1) The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicityPloS oneJanuary 1, 2014Szalóki G, Krasznai ZT, Tóth Á, Vízkeleti L, Szöllősi AG, Trencsényi G, Lajtos I, Juhász I, Krasznai Z, Márián T, et al.

(2) Pgp inhibition by UIC2 antibody can be followed in vitro by using tumor-diagnostic radiotracers, 99mTc-MIBI and 18FDGEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical SciencesDecember 23, 2010Krasznai ZT, Tóth A, Mikecz P, Fodor Z, Szabó G, Galuska L, Hernádi Z, Goda K.

(3) Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibodyThe Journal of pharmacology and experimental therapeuticsJanuary 1, 2007Goda K, Fenyvesi F, Bacsó Z, Nagy H, Márián T, Megyeri A, Krasznai Z, Juhász I, Vecsernyés M, Szabó G Jr.

(4) Detection of P-glycoprotein in squamous cell carcinomas of the head and neckArchives of otolaryngology--head & neck surgeryApril 1, 1993Kelley DJ, Pavelic ZP, Gapany M, Stambrook P, Pavelic L, Gapany S, Gluckman JL.

(5) Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibodyProceedings of the National Academy of Sciences of the United States of AmericaJuly 1, 1992Mechetner EB, Roninson IB.

Be the First to Write a Review!